Business Context and Reporting Period
Bicycle Therapeutics plc filed a Form 8-K reporting material agreements entered into on July 9, 2021. The filing was signed on July 13, 2021 and concerns a strategic collaboration with Ionis Pharmaceuticals, Inc. focused on TfR1 Bicycle peptides for oligonucleotide delivery.
Key Financial and Transaction Metrics
- Ionis will pay Bicycle an upfront collaboration payment of $31.0 million.
- Ionis will make an equity investment of approximately $11.0 million by purchasing 282,485 ordinary shares at $38.94 per share.
- Ionis previously paid a $3.0 million option fee under the December 31, 2020 Evaluation and Option Agreement.
- Bicycle is eligible for additional low-single-digit-million-dollar payments upon acceptance of investigational new drug applications, subject to a high-single-digit-million-dollar credit applicable to four targets.
- Bicycle may receive development and regulatory milestone payments of up to a low-double-digit-million-dollar amount per collaboration target and cumulative sales milestones of up to a low-double-digit-million-dollar amount.
- Bicycle is eligible for tiered royalties on net sales at percentages in the low single digits, subject to customary reductions and offsets.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet figures for a comparable reporting period.
Material Changes and Agreement Terms
- Bicycle granted Ionis a worldwide exclusive license to research, develop, manufacture, and commercialize TfR1 Bicycles for delivery of Ionis-selected oligonucleotide compounds.
- Ionis will assume responsibility for future research, development, manufacturing, and commercialization after the parties’ initial optimization and discovery activities.
- Bicycle retained rights to use TfR1 Bicycles for non-oligonucleotide therapeutic purposes.
- The share purchase is intended to qualify for the private-placement exemption under Section 4(a)(2) of the Securities Act; the shares were not registered.
- Ionis agreed to standstill restrictions generally expiring 18 months after the share purchase agreement and transfer restrictions generally lasting until the earlier of one year after closing or termination of the collaboration, subject to stated exceptions.
Outlook, Risks, and Unusual Items
Potential future payments depend on target selection, IND acceptance, development and regulatory milestones, sales milestones, and product commercialization. Either party may terminate for an uncured material breach or insolvency; Ionis may also terminate for convenience, in whole or by target, subject to specified notice periods.
Key risks include delays associated with the COVID-19 pandemic, unsuccessful preclinical or clinical development, failure to obtain regulatory approvals, inability to realize the intended benefits of the technology or collaboration, failure to meet milestones, and conditions affecting completion of the share sale. The filing states that actual results may differ materially from forward-looking statements.
Important Facts to Verify
- Confirm completion and closing date of Ionis’s approximately $11.0 million equity investment.
- Verify receipt and accounting treatment of the $31.0 million upfront payment and any applicable revenue-recognition obligations.
- Review the definitive collaboration and share purchase agreements when filed as exhibits in a subsequent SEC filing.
- Assess the status of TfR1 Bicycle research, target selection, IND submissions, and associated milestone eligibility.
- Review the company’s subsequent SEC filings for changes in collaboration status, termination rights, royalties, liquidity, and financial results.